Angiogenesis and angiogenic mediators in haematological malignancies.
Mangi
M H
MH
Department of Haematology, The Royal London Hospital, Whitechapel, UK. m.h.mangi@mds.qmw.ac.uk
Newland
A C
AC
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002648:Child; D016207:Cytokines / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000502:physiology*; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000502:physiology*; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000150:complications* / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016207:Cytokines; D003603:Cytotoxins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors